PAEDIATRIC OBESITY PREVENTION, NUTRITION AND DIETETICS
With
Dr Robyn Littlewood, Chief Executive,
Health and Wellbeing Queensland & Adjunct Professor, University of Queensland, Queensland University of Technology & Griffith University, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | December 2025
Dr Robyn Littlewood is the CEO of Health and Wellbeing Queensland, the state’s prevention agency committed to fostering a healthier and more equitable Queensland.
With over 25 years of experience in clinical care, research and education, Dr Littlewood has made significant contributions to paediatric healthcare. Dr Littlewood is a published author with over 100 publications and has recently released her first book on health and wellbeing for Queensland. She has trained hundreds of students over two decades of frontline service.
Leveraging a systems-based and collaborative approach, Dr Littlewood continues to drive research and data outcomes in the area of health and wellbeing. Dr Littlewood leads a dedicated team focused on making healthy happen for all Queenslanders, with a particular focus on improving health outcomes for our next generation.
Dr Littlewood holds a raft of formal qualifications including a Bachelor of Science and Postgraduate Diploma in Nutrition and Dietetics, a Master of Medical Science, a Masters of Business Administration and a PhD. Dr Littlewood has also completed a number of postgraduate qualifications in executive leadership and is a member of the Australian Institute of Company Directors. Dr Littlewood holds Adjunct Professor appointments from UQ, QUT and Griffith universities, has been awarded Fellow of Dietitians Australia, the Barbara Chester Award and QUT Health Alumni of the year in recognition of her outstanding contribution to the dietetics profession.
Source: Supplied
https://orcid.org/0000-0002-9955-3662
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Corneal and Ocular Surface Immunology and Regeneration
Assoc Professor Holly Chinnery’s career in ocular immunology began with a focus on animal models; however, it has recently transitioned into clinical imaging studies involving human research participants. The ability to visualise the immune system and sensory nerves in the human cornea represents a significant advantage in corneal immunology and neuroimmunology research.
